Company intelligence / Profile preview

Gallixa LLC

Menlo Park, California, United Statesgallixa.com ↗

Ownership: Private
Development stage: Commercial

Overview

GALLIXA® has demonstrated anecdotal clinical efficacy in treating chronic pain and inflammatory skin conditions with no observed adverse effects. The company controls all preclinical and clinical data regarding oral gallium maltolate. No formal large-scale trial results are published yet[1].

Therapeutic areas: DermatologyRheumatologyNeurology
Modalities: Small molecules (specifically gallium maltolate in topical formulation)
Industry: Biotech

Drug pipeline

1 asset

gallium maltolate

Commercial

Indications: Skin conditions, Pain management

Partnerships

Potential for future partnerships/licensing with established pharmaceutical companies mentioned but none confirmed as of now[1]

Beyond the preview

Go deeper on Gallixa LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gallixa LLC.

Explore the full profile